More evidence that gal continually and irresponsibly misleads others. She does Zogenix no favors and, if I could mind read management, Zogenix is horrified that someone so incompetent is acting as their advocate on this mb. And when she posts her own thoughts why is her language that of a high school girl? "Disgusting" "filthy" "nasty", "Jane poo poo" " I wuv you Roger", " you are my hero sir", laughing out loud when she fakes ownership of a stock that just went up that day "I love you Annie LOL" I luv you Tim LOL". (Sigh).
You haven't been shy about telling the number of shares you bought. So how many did you sell? Also you mentioned you have sources regarding this stock. What are they telling you now?
Another press release. This news is what was promised on their cc and the Morgan Stanley conference. I feel uncomfortable that the press release here describes the news as "good" when it used to be described as "great". Is this an unpcoming news downgrade?
That's why it's so tough to make it in a career as a comic. The trends change quickly and, if you don't keep up, next thing you know, you're booed and heckled or get lots of thumbs down.
Not beating up, just reiterating what was said. (Though I thought the "I thought she sold her car" quip was not bad.)
I sure hope she sold it. That money is needed to provide pain meds for children in foreign countries, who are her "dear loved ones" who she promised to help.
Post from stockgal:
"Just to note.....my [car] I was worth more toward $500,000 not $300,000 did I tell you that people worldwide suffering in pain.....they do NOT received any pain medications. This is horrendous......India my love to India....I shall do my best to assure proper access to appropriate relief dear loved ones. Children of foreign countries ....my heart is with you. I will sell my car....and begin overseas program to insure esp. children in pain get help first."
Very nice sentiments if a tad bit theatrical. These sentiments might be a bit more meaningful if the children of India and other foreign countries who you were addressing actually read the Zogenix yahoo message board. Like your stock trades, you didn't need to share this and your car value with us either. Unless you do.
Ahh good old stockygal. I like this quote of yours : " I never share my trades with people here. Nor do I have to." But you didn't finish your thought. I'll do it for you: " But what I, stockgal, have to do is share with everyone those stocks that go up huge and pretend I own them so I, stockgal, will be respected as a successful trader, DD expert and individual." DD is more than receiving emails and press releases from others and posting them as if you wrote them. You have issues to resolve. Until you do, you are the fraud.
Sorry, doesn't pass the laugh test. You have a record of posting stocks on the day they're up not just big, but those that are up huge and acting like you have owned them all along. Good idea for image creation though.
It was curious that last week you called someone the last name "Berg" as if you were insulting them. Why do you consider that name an insult?
Point being the FDA didn't consider that propaganda when approving Zohydro and they won't consider it when deciding approval for any other opiod under review.
As a doctor responded to Andrew Kolodny when Kolodny described Zohydro in the same way, why would a child be taking it?
From January 2013:
FDA issues draft guidance on abuse-deterrent opioids
The U.S. Food and Drug Administration today issued a draft guidance document to assist industry in developing new formulations of opioid drugs with abuse-deterrent properties.
The document “Guidance for Industry: Abuse-Deterrent Opioids – Evaluation and Labeling,” explains the FDA’s current thinking about the studies that should be conducted to demonstrate that a given formulation has abuse-deterrent properties, how those studies will be evaluated by the agency, and what labeling claims may be approved based on the results of those studies.
“The FDA is extremely concerned about the inappropriate use of prescription opioids, which is a major public health challenge for our nation,” said FDA Commissioner Margaret A. Hamburg, M.D. “This draft guidance is an important part of a larger effort by FDA aimed at preventing prescription drug abuse and misuse.”
Opioids can be abused in a number of ways. Abuse-deterrent formulations target the known or expected routes of abuse, such as crushing in order to snort or dissolving in order to inject, for the specific opioid drug substance in that formulation. The science of abuse deterrence is relatively new, and both the formulation technologies and the analytical, clinical, and statistical methods for evaluating those technologies are rapidly evolving. In working with industry, the FDA will take a flexible, adaptive approach to the evaluation and labeling of potentially abuse-deterrent products.
“While prescription opioids are an important component of pain management, abuse and misuse of these products have resulted in too many injuries and deaths across the United States,” said Douglas Throckmorton, M.D., deputy director for regulatory programs in the FDA’s Center for Drug Evaluation and Research. “An important step towards the goal of creating safer opioids is the development of products that are specifically formulated to deter abuse.”
The FDA continues to encourage the development of abuse-deterrent formulations of opioids and believes that these products have promise to help reduce prescription drug abuse. At the same time, the FDA remains committed to ensuring that patients with pain have appropriate access to opioid analgesics.
This draft guidance fulfills mandates under the Food and Drug Administration Safety and Innovation Act (FDASIA) and the Office of National Drug Control Policy’s (ONDCP) Prescription Drug Abuse Prevention Plan.
“Our nation is in the midst of a prescription drug abuse epidemic,” said Gil Kerlikowske, director of National Drug Control Policy. “While there are no silver bullet solutions to this public health and safety challenge, abuse-deterrent formulations of powerful prescription opioids can make a difference in addressing this epidemic. This guidance is a vitalcomponent of the Administration’s comprehensive effort to reduce prescription drug abuse in America, and we commend the FDA for its commitment to this challenge.”
Regarding your point that management would not have invested so much if they did not think it would work out, sure, management expected that they would leverage the Sumavel DosePro business with additional pain products, ZohydroER being the hopefully unique blockbuster. But they did not expect or prepare for the backlash that happened and they should have. Before Zohydro was even approved, there were town hall meetings all over this country discussing the heroin epidemic with prescription opiod abuse being identified as a major cause. And now Sumavel has been sold off and company strategy has gone from partnership to going it alone with a larger sales force back to soon to be announced partnerships again. And, all the while, legal issues and strategies continue to be at the forefront when management would have expected a few years back that, by now, sales strategy would be the only company focus. The more important risk issue to observe now is NOT if Zohydro and other pipeline products will be moneymakers but when they will be profit makers.
That's an example why I am still trying to stay disciplined waiting for a 30% increase or so from whatever turns out to be the low before I add more. (The lower it may go, if it does, the higher % to the upside I need to see.) That could happen on a Purdue delay or CRL or, if their drug happens to be approved , then I'm free to make decisions then. That's why I think announcement of partnership(s) and SNDAs mean little for the upside other than a temporary bump. The reason is, this stock has been seriously crushed at least twice since it's been publicly traded and, during that time, partnerships were used and NDAs submitted with high expectations. From now on IMO announcements only go so far. I agree attacks are being overcome but specific bottom line results from those partnerships that significantly exceed expectations are the only information that will renew confidence in this stock to push it back to it's highs. All IMO of course.